Media headlines about Neuralstem (NASDAQ:CUR) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neuralstem earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.6162836254651 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Separately, ValuEngine raised shares of Neuralstem from a “sell” rating to a “hold” rating in a report on Friday, June 9th.

Neuralstem (NASDAQ CUR) traded down 4.55% during trading on Monday, reaching $1.26. The company’s stock had a trading volume of 70,979 shares. The stock has a 50 day moving average price of $1.18 and a 200 day moving average price of $3.98. Neuralstem has a 1-year low of $0.22 and a 1-year high of $6.60. The stock’s market capitalization is $15.27 million.

Neuralstem (NASDAQ:CUR) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($9.49) by $9.10. Neuralstem had a negative return on equity of 321.78% and a negative net margin of 198,573.91%. Analysts anticipate that Neuralstem will post ($2.26) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Neuralstem (CUR) Stock Price” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at

About Neuralstem

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Insider Buying and Selling by Quarter for Neuralstem (NASDAQ:CUR)

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.